Point72 Asset Management
AQST icon

Point72 Asset Management’s Aquestive Therapeutics AQST Stock Holding History

Point72 Asset Management’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.18M Buy
+283,734
New +$1.15M ﹤0.01% 2662
2018
Q4 		– Sell
-20,000
Closed -$350K – 952
2018
Q3 		$350K Buy
+20,000
New +$330K ﹤0.01% 946

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Point72 Asset Management's AQST Position: Q1 2026 in Review

Point72 Asset Management opened a new position in Aquestive Therapeutics (AQST) in Q1 2026: 283,734 shares worth $1.18M. The stake represents ﹤0.01% of the portfolio and ranks #2662 among its holdings. This is a return to the name: Point72 Asset Management previously reported a position in AQST as recently as Q3 2018.

Point72 Asset Management first reported a position in AQST in Q3 2018 and has held it in 2 quarters since. 179 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

  • Point72 Asset Management held 283,734 shares of Aquestive Therapeutics worth $1.18M as of Q1 2026.
  • Aquestive Therapeutics was a new Point72 Asset Management position in Q1 2026.
  • Aquestive Therapeutics made up ﹤0.01% of Point72 Asset Management's portfolio in Q1 2026, its #2662 holding.
  • Point72 Asset Management first reported a position in Aquestive Therapeutics in Q3 2018 and has held it in 2 quarters since.
  • 179 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.